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Abstract
Aggressive periodontitis (AgP) is a rapidly progressing type of periodontal disease in otherwise healthy individuals which
causes destruction of the supporting tissues of the teeth. The disease is initiated by pathogenic bacteria in the dental
biofilm, and the severity of inflammation and attachment loss varies with the host response. Recently, there has been an
increased interest in determining the role of lipid mediators in inflammatory events and the concept of pro-inflammatory
and pro-resolution lipid mediators has been brought into focus also in periodontal disease. The present study aimed to
determine the profile of omega-3 or n3- as well as omega-6 or n6- polyunsaturated fatty acids (PUFAs) and PUFA-
metabolites of linoleic acid, arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in gingival
crevicular fluid (GCF), saliva and serum in AgP patients and healthy controls. In total, 60 selected n3- and n6-PUFAs and
various PUFA metabolites were measured using high performance liquid chromatography-tandem electrospray ionisation
mass spectrometry (HPLC-ESI-MS-MS). Of these, 51 could be quantified in this study. The concentrations of the majority
were low in saliva samples compared with serum and GCF, but were mainly higher in AgP patients compared with healthy
controls in all three kinds of sample. Ratios of n3- to n6-PUFAs (DHA + EPA)/AA were significantly lower in the GCF of AgP
patients than in the healthy controls. Furthermore, various ratios of the direct precursors of the pro-resolution lipid
mediators (precursors of resolvins and protectins) were calculated against the precursors of mainly pro-inflammatory lipid
mediators. These ratios were mainly lower in GCF and saliva of AgP patients, compared with healthy controls, but only
reached significance in GCF (P,0.05). To conclude, the ratios of precursors of pro-resolution/pro-inflammatory lipid
mediators seem to be more relevant for describing the disease status of AgP than the concentration of specific lipid
mediators.
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Introduction
Aggressive periodontitis (AgP) is a rapidly progressive form of
inflammatory periodontal disease. If not treated, AgP may result in
tooth loss even in young people [1]. The initiating factors of
periodontal disease are bacteria and bacterial products which form
a biofilm covering the tooth surface in the subgingival area. In
susceptible individuals, the host-mediated response to the patho-
genic flora is subsequently responsible for the periodontal tissue
destruction [2,3]. The course of the disease is modified by different
environmental factors, and the patient’s genetic make-up contrib-
utes to patient susceptibility, in particular in the case of aggressive
forms of periodontitis [4–6].
Persistence of inflammation or the failure of tissue to return to
the normal state favours tissue destruction [7]. Thus, resolution of
inflammation is essential to the process of regaining tissue
homeostasis after infection, and it has become clear that this is
not a passively, but an actively coordinated process involving
several biochemical pathways, enzymes and mediators [8,9]. Over
recent years, there has been an increased interest in determining
the role of lipid mediators in anti-inflammatory events, and the
concept of pro-inflammatory and pro-resolution lipid mediators
has also been brought into focus in periodontal disease pathogen-
esis [10].
Host factors, including both immune components and resident
cells, contribute to tissue destruction via synthesis and release of
different pro-inflammatory molecules [11]. The pathogens trigger
the cell membrane of the immune cells, leading to the release of
free fatty acid, mainly arachidonic acid (AA). Pro-inflammatory
lipid mediators such as thromboxanes (TX), prostaglandins (PG)
and leukotrienes (LT), as well as anti-inflammatory lipid mediators
such as lipoxins (LX), are among the products generated, mainly
via AA-metabolism.
Arachidonic acid is metabolized to biologically active eicosa-
noids through the cyclooxygenase pathway (COX-1 and COX-2),
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which results in production of various PG-like PGE2 and PGD2
[12,13]. Other mediators such as LT, particularly LTB4, arise
through the conversion of hydroxyeicosatetraenoic acid (HETE)
by 5-lipoxygenase (5-LOX). The AA-derived prostanoids and LT
are associated with the destruction of collagen and bone resorption
occurring in periodontal disease [14,15]. Lipoxygenases involved
in AA, EPA and DHA metabolism are the 5-LOX, 12-LOX and
15-LOX. The human 12-LOX can be classified into two types, the
platelet type and the epidermis type [16,17] while the human type
can be classified into the reticulocyte type (15-LOX-1) [18],
leukocyte type [19], and the epidermis type (15-LOX-2) [20,21].
Prostaglandins are biological mediators involved in inflammation
and have been implicated as stimulators of bone loss [8]. Levels of
PGE2 are significantly elevated in the gingival crevicular fluid
(GCF) of patients with periodontal disease. High levels of PGE2
are associated with disease aggressiveness and constitute a reliable
indicator of current clinical periodontal destruction [14,15]. High
levels of LTB4 have also been found in periodontal inflamed
tissues and are considered to be an indicator of periodontal
inflammation [14].
Omega-6 (n6) and omega-3 (n3) polyunsaturated fatty acids
(PUFAs) are substrates for the production of various eicosanoids
and docosanoids (Figure 1). The mono-hydroxylated PUFA
metabolites of AA, 15-HETE and 5-HETE are direct precursors
for LXs, which, in contrast to PGs and LTs, attenuate the
inflammatory effect [22,23]. The major n3-PUFAs are eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA), which
are the precursors of various novel pro-resolution lipid mediators
like resolvins (Rv), protectins (PD) and maresins (MaR) which are
responsible for the active resolution of inflammation [24–27]. The
PUFAs EPA and DHA are substrates for various classes of Rv of
the E (originating from EPA) and D (originating from DHA) series,
respectively [28]. Interestingly, local application of RvE1, which is
one of the bioactive pro-resolution mediators, reduced inflamma-
tion and promoted regeneration of pathologically lost tissues in a
rabbit model of periodontal disease [29]. In humans, the daily
dietary supplementation of n3-PUFAs in combination with aspirin
was reported to reduce the frequency of deep periodontal pockets
and inflammatory lipid mediators in saliva [30].
Little is known about the presence and the amount of different
bioactive lipid mediators in oral fluids during periodontal
inflammation and its resolution. In particular, a comparison
between their levels locally near the inflamed site (in GCF and
saliva) and systemically (in serum) has, to our knowledge, not been
done. In this report, we analysed eicosanoids and docosanoids in
GCF, saliva and serum in a group of AgP patients and healthy
controls in an attempt to understand better the roles and
relationships of these lipid mediators.
Results
In the present study the levels of various PUFAs and mono-
hydroxylated PUFA metabolites and pro-resolution and pro-
inflammatory lipid mediators in GCF, saliva and serum samples
from AgP patients and healthy controls were measured by high
performance liquid chromatography – electrospray ionization
Figure 1. PUFA-metabolites and lipid mediators originating from the n6- and n3-polyunsaturated fatty acids (PUFAs). In addition,
bioactive pro-resolving as well as pro-inflammatory eicosanoids and docosanoids were marked in red or green, respectively. Abbreviations: AA:
arachidonic acid; ALA: alpha-linolenic; DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid; HEPE: hydroxyeicosapentaenoic acid; HETE:
hydroxyeicosatetraenoic acid; HDHA: hydroxydocosahexaenoic acid¸ LA: linoleic acid; LT: leukotriene; LX: lipoxin, HODE: hydroxyoctadecadienoic acid;
HX: hepoxilin; MaR: maresin; PD: protectin; PG: prostaglandin; Rv: resolvin; TX: thromboxane.
doi:10.1371/journal.pone.0070838.g001
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Table 1. Concentration of lipid mediators in GCF samples.
AgP HC P value
(n =16) ng/ml (n=12) ng/ml
PUFAs AA 15.5615.5 2.762.3 0.001*
EPA 0.260.2 0.160.0{ 0.012*
DHA 1.060.7 0.460.2 0.046*
LA 17.268.6 9.764.7 0.007*
5-lipoxygenase pathway 5-HETE 0.160.1 0.160.0{ 0.179
LTB4 0.160.1 0.160.0{ 0.113
20-OH-LTB4 0.460.5 0.260.2 0.690
20-COOH-LTB4 3.162.7 2.164.5 0.054
LTC4 0.160.1 0.160.1{ 0.780
5-oxoETE** 0.660.6 0.360.3{ 0.055
LXB4 0.160.1 0.160.1{ 0.960
LXA4 0.260.4 0.160.1{ 0.146
5-HEPE 0.160.1 0.160.0{ 0.120
LTB5 0.260.1 0.160.1{ 0.646
LXA5 0.260.3 0.360.3{ 0.129
4-HDHA 0.160.0 0.160.0{ 0.120
8-hydroxylation pathway 8-HETE 0.160.1 0.160.0{ 0.037*
8-HEPE 0.160.1 0.160.1{ 0.258
10-HDHA 0.160.1 0.160.1{ 0.356
PD1 0.160.1 0.160.0{ 0.903
12-lipoxygenase pathway 12-HETE 1.160.9 0.660.7{ 0.039*
12-oxoETE** 0.861.3 0.960.7{ 0.200
HXA3 0.760.7 0.861.1{ 0.815
HXB3 0.961.1 1.060.9 0.655
12-HEPE 0.160.2 0.160.0{ 0.020*
14-HDHA 0.160.0 0.160.1{ 0.331
RvD1 0.360.4 0.260.1{ 0.848
RvD2 0.860.7 0.760.4{ 0.422
MaR 0.160.1 0.160.1{ 0.533
9-HODE 6.366.4 2.661.6 0.029*
15-lipoxygenase pathway 15-HETE 1.562.0 0.160.1{ 0.001*
15-oxoETE** 1.661.8 0.260.2{ 0.050
15-HEPE 0.260.2 0.160.0{ 0.042*
17-HDHA 0.260.3 0.160.0{ 0.010*
13-HODE 14.6613.0 4.963.1 0.009*
13-oxoODE** 14.4617.4 14.669.2 0.486
Cyclooxygenase pathway PGD2 0.960.8 1.361.0{ 0.429
PGE2 2.261.6 0.760.5 0.008*
d15d12PGD2 0.160.1 0.160.2{ 0.823
PGJ2 0.160.1 0.160.1{ 0.785
d15d12PGJ2 0.160.0 0.160.0{ 0.212
TXB2 0.160.1 0.160.1{ 0.674
PGF2 0.360.3 0.260.2{ 0.571
PGE3 1.861.9 1.361.3 0.632
Alternative pathways 20-HETE 0.360.2 0.260.2{ 0.056
20-COOH-AA 0.860.7 0.360.4{ 0.044*
18-HEPE 0.961.9 1.261.7{ 0.118
20-HDHA 0.260.2 0.160.1{ 0.269
11-HETE 0.160.0 0.160.0{ 0.020*
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combined with tandem mass spectrometry (HPLC-ESI-MS-MS)
and enzyme-linked immunosorbent assay (ELISA). Not all samples
could be analysed, and the final numbers of individuals analysed
for each sample type are specified in Tables 1, 2 and 3. In total for
each individual, 60 lipids were measured using the HPLC-ESI-
MS-MS method and 51 could be quantified in the biological
liquids. The concentrations of these lipids were lower in saliva
samples (Table 2) compared with both serum (Table 3) and GCF
samples (Table 1). Levels of these lipids were increased in most
biological samples of AgP patients compared with healthy controls,
although not all results were statistically significant.
GCF analysis
Both n6-PUFAs (linoleic acid (LA) and AA) and n3-PUFAs
(EPA and DHA) were detected at significantly higher concentra-
tions in the GCF of AgP patients than in healthy controls (Table 1).
Furthermore, the 12-LOX pathway metabolites like 12-HETE,
12-hydroxyeicosapentaenoic acid (12-HEPE), 9-hydroxyoctadeca-
noic acid (9-HODE) and 14-hydroxydocosahexaenoic acid (14-
HDHA); the 15-LOX metabolites 15-HETE, 13-HODE, 15-
HEPE and 17-HDHA and various other PUFA metabolites like
11-HETE, 20-COOH-AA and the oxidative stress marker 8iPGF2
were all present at enhanced concentrations (significantly different)
in AgP patient samples (Table 1). Finally and interestingly, the
concentration of the COX-pathway metabolite PGE2 was
significantly higher in GCF samples of AgP patients
(2.261.6 ng/ml) compared with healthy controls (0.760.5 ng/
ml) (P=0.008) (Table 1).
The GCF samples were additionally analysed by ELISA for
PGE2 and LXA4. The levels of PGE2 were significantly increased
in patients (mean 5.661.3 ng/ml) compared with healthy controls
(mean 4.760.7 ng/ml) (P=0.002), which was in line with the
HPLC-ESI-MS-MS results. By use of ELISA, the LXA4 concen-
trations between patients and healthy controls was slightly lower in
GCF of AgP compared with healthy controls (P=0.049) (Figure 2).
Saliva analysis
From the PUFA levels of LA, AA, EPA and DHA were found at
slightly higher concentration in saliva samples of AgP patients
compared with controls (Table 2). Lipid derivatives originating
from the 5-LOX pathways, in particular LTB4 (P=0.002), 20-
OH-LTB4 (P=0.048), 5-HETE (P=0.017), 5-oxoETE and from
the 15-LOX pathways, 15-HETE (P=0.004), 15-oxoETE and 17-
HDHA, were found in higher concentrations in AgP patients
(Table 2). In contrast, 12-oxoETE was present in significantly
lower concentrations in the patient group. The concentrations of
PGE2 in saliva in AgP patients and healthy controls were not
significantly different.
Serum analysis
As with GCF, the levels of the fatty acids in serum including AA,
EPA, DHA and LA, were higher in AgP patients (Table 3). Several
PUFA metabolites originating from various LOX pathways, in
particular 5-HETE, 8-HETE, 12-HETE, 15-HETE, HXA3, 9-
HODE, 13-HODE, 13-oxoODE, 5-oxoETE, 15-oxoETE, LXA4,
5-HEPE, 12-HEPE, 8-HEPE, 4-HDHA, 10-HDHA, 14-HDHA
and 17-HDHA were increased in AgP patient samples compared
with healthy controls (Table 3). The concentration of the lipid
mediator d15d12PGD2, a COX metabolite, was increased in the
serum samples of AgP patients, as well as 20-COOH-AA, 20-
HDHA and 11-HETE (Table 3). In general, concentrations of
various PUFA metabolites were much higher in serum than in
saliva and GCF.
Ratios of precursors of pro-resolution/pro-inflammatory
lipid mediators and LOX/COX-pathway analysis
There were considerable variations of the concentrations of
DHA, EPA and AA between groups in GCF, saliva and serum
analysed in this study (Table 1, 2 and 3). The ratio of the n3-
PUFAs (DHA and EPA) concentration vs. the concentration the
n6-PUFA (AA) in GCF was significantly lower in AgP compared
with the control group (P=0.004) (Figure 3A). By contrast, there
was no significant difference in these ratios in saliva and serum
(Figure 3B and C).
In addition the ratio of the direct precursors of pro-resolution
lipid mediators (14-HDHA, 17-HDHA and 18-HEPE), which are
precursors of resolvins and protectins, was calculated against
various precursors of the AA-derived and mainly pro-inflamma-
tory derivatives (5-HETE, 12-HETE and 15-HETE) as well as
ratios of sum of HEPEs and sum of HDHAs vs. the sum of HETEs
were calculated (Table 4). The ratio of precursors of pro-resolution
to pro-inflammatory lipid markers (HEPE/HETE and HDHA/
HETE) were mainly reduced in the GCF, saliva and serum of AgP
patients in comparison with healthy controls but was just
significant in GCF samples (P,0.05) (Table 4).
The sum of 5-, 12-, 15-LOX and COX pathway originating
metabolites were mainly upregulated in serum, GCF and saliva
samples from AgP compared with healthy controls (Table 4).
Discussion
To draw a general picture of the contribution of bioactive lipid
mediators in periodontal health and disease, lipid mediators were
profiled using the HPLC-ESI-MS-MS methodology for serum,
saliva and GCF samples from AgP patients and healthy controls.
The precise concentration of PUFAs, PUFA metabolites and
further lipid mediators determined using lipidomic technology
leads to a deeper understanding of the role of lipid mediators in
the mechanism of periodontal disease [31]. In this study, we report
Table 1. Cont.
AgP HC P value
(n =16) ng/ml (n=12) ng/ml
Oxidative stress marker 8iPGF2 0.260.2 0.160.1{ 0.021*
8iPGF3 0.860.7 0.760.7 0.722
The concentration of lipid mediators in gingival crevicular fluid (GCF) of aggressive periodontitis (AgP) patients and healthy controls (HC) was measured by HPLC-MS-
MS. Results in ng/ml are expressed as mean6 SD. * Significantly different (P,0.05, Mann Whitney test). {Various values below the quantification limit set to 0.05 ng/ml.
** These derivatives may partly origin from autooxidation.
doi:10.1371/journal.pone.0070838.t001
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Table 2. Concentration of lipid mediators in saliva samples.
AgP HC P value
(n =16) ng/ml (n=12) ng/ml
PUFAs AA 12.24611.15 7.3865.22 0.108
EPA 0.2060.31 0.0760.06{ 0.102
DHA 1.1961.73 0.8760.60 0.477
LA 2.9862.39 2.7762.53 0.793
5-lipoxygenase pathway 5-HETE 0.2360.27 0.066 0.08{ 0.017*
LTB4 0.4760.41 0.1260.15{ 0.002*
20-OH-LTB4 0.5760.93 0.1360.13{ 0.048*
20-COOH-LTB4 0.2960.30 0.3260.35{ 0.832
LTC4 0.0260.00 0.0260.00{ –
5-oxoETE** 0.0660.05 0.0360.02{ 0.012*
LXB4 0.0260.00 0.0260.00{ –
LXA4 0.0560.09 0.0260.01{ 0.302
5-HEPE 0.0260.00 0.0260.00{ 0.737
LTB5 0.0260.00 0.0260.00{ 0.364
LXA5 0.0260.01 0.0260.00{ 0.264
4-HDHA 0.0260.00 0.0260.00{ 0.224
8-hydroxylation pathway 8-HETE 0.1760.21 0.1660.32{ 0.913
8-HEPE 0.0460.06 0.0260.01{ 0.269
10-HDHA 0.0360.01 0.0260.00{ 0.047*
PD1 0.0360.02 0.0260.00{ 0.085
12-lipoxygenase pathway 12-HETE 3.0562.49 2.4163.09{ 0.488
12-oxoETE** 1.1161.57 1.5761.38{ 0.362
HXA3 0.7361.14 0.2560.54{ 0.120
HXB3 0.6962.09 0.2860.50{ 0.436
12-HEPE 0.1260.14 0.3160.95{ 0.365
14-HDHA 0.1360.13 0.1360.15{ 0.915
RvD1 0.0260.00 0.0260.01{ 0.295
RvD2 0.0360.02 0.0360.03{ 0.391
MaR 0.0260.00 0.0260.00{ 0.284
9-HODE 0.3160.35 0.2660.49 0.759
15-lipoxygenase pathway 15-HETE 0.2260.43 0.0360.02{ 0.004*
15-oxoETE** 0.1260.21 0.0260.02{ 0.068
15-HEPE 0.0260.00 0.0260.00{ 0.203
17-HDHA 0.0460.03 0.0260.01{ 0.036*
13-HODE 0.4360.45 0.4460.72 0.965
13-oxoODE** 11.65611.82 14.66619.76 0.570
Cyclooxygenase pathway PGD2 0.1160.09 0.0860.10{ 0.333
PGE2 0.1760.26 0.0860.06{ 0.142
d15d12PGD2 0.0260.00 0.0260.01{ 0.327
PGJ2 0.0260.01 0.0260.00{ 0.571
d15d12PGJ2 0.0360.03 0.0260.00{ 0.364
TXB2 0.0860.10 0.0560.06{ 0.334
PGF2 0.0360.02 0.0260.01{ 0.032*
PGE3 0.0960.11 0.0860.12{ 0.764
Alternative pathways 20-HETE 0.0260.00 0.0260.00{ 0.252
20-COOH-AA 1.7661.95 0.9160.65{ 0.093
18-HEPE 0.0360.02 0.0260.00{ 0.138
20-HDHA 0.0460.04 0.0260.01{ 0.261
11-HETE 0.0960.15 0.0260.01{ 0.083
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mainly elevated levels of n6- and n3-PUFAs as well as various
eicosanoids and docosanoids in serum, GCF and saliva of AgP
patients compared with the healthy controls. On the other hand,
the ratio of the concentrations of precursors of pro-inflammatory
or pro-resolving lipid mediators from n3-PUFAs vs. concentrations
of n6-PUFAs (DHA and/or EPA)/AA were lower in GCF samples
of AgP patients compared with healthy controls, which was the
main novel finding in the present study.
EPA and DHA concentrations were significantly higher in AgP
patients when compared with the healthy controls. Figueredo
et al. [32] also reported of significantly higher levels of EPA and
DHA in serum of patients with generalized chronic periodontitis
compared with that of patients with gingivitis. Whereas there were
significantly lower EPA/AA and DHA/AA ratios in GCF of the
AgP patients compared to healthy controls, this was not the case in
serum and saliva samples in which approximately similar ratios in
AgP patients and controls were demonstrated. In a previous study
it was reported that in periodontitis patients with bone loss, the
serum levels of fatty acids from the n6-PUFA pathways, which
were obtained after saponification, were higher than in healthy
individuals, whereas the opposite was observed with fatty acids of
the n3-PUFA pathway [22]. The bone loss was linked to an
imbalance between the two pathways with mainly an increase in
AA and a decrease in EPA and DHA.
Recently the active resolution of inflammation was recognized
as a process driven by lipoxins originating from AA and novel
compounds from EPA and DHA known as resolvins, which have a
potential to dampen or resolve the damaging aspects of the
inflammatory response. LXA4 is an endogenous lipid mediator
which plays an important role in the local resolution processes
[7,33]. In the present study, we found LXA4 concentration to be
increased in patients compared with healthy controls when
measured by HPLC-ESI-MS-MS, but this was significant only in
serum samples. LXA4 in GCF was also determined by ELISA.
Using this technique, LXA4 was identified at slightly higher
concentrations in healthy controls (P=0.049), but the difference
was minor. The pro-resolution lipid mediators such as RvD1,
MaR and PD1 were detected either at very low concentrations or
were below the detection limit. This can be explained either by
their instability during sample collection and storage or simply by
very low and undetectable endogenous concentrations with
current analytical technologies [34,35]. Recently, the ‘‘Serum
Metabolome Project’’ identified 65 lipids by LC-MS [36]. RvE1
and RvD1 were among the lipid mediators identified in plasma of
systemically healthy individuals with unknown periodontal status.
Whereas these molecules have regulator functions in inflamma-
tion, the importance of circulating levels of these molecules is
debated [36].
In the present study, RvD1, RvD2 and PD1 were determined in
serum samples of AgP patients and healthy controls, with
comparable RvD1 level. Recently, RvD1 and RvD2 were detected
in the serum samples of healthy individuals having oral n3-fatty
acid supplementation, while PD1 was below the detection limit
[37]. Notably, in the present study, there was no n3-PUFAs
supplementation of AgP patients or healthy controls. The
precursor of RvE1 18-HEPE may represent the EPA-derived
resolving capacity [37].
AA was present in higher concentrations in GCF samples of
AgP patients than in controls. The main AA-derived pro-
inflammatory lipid mediators are prostaglandins and leukotrienes.
They are important biological mediators involved in the inflam-
matory response, as well as in regulation of bone formation and
bone resorption. PGE2 has been proposed as a measure of disease
status in GCF [32]. In our study, PGE2 was present at higher
concentrations in GCF samples of AgP patients than in controls,
which is in line with a previous study in which PGE2
concentration was significantly increased in GCF during the
active phase of the disease [14]. Relatively small differences in
PGE2 levels (ng/ml) were observed when comparing AgP patients
with healthy controls in the current analysis. The mean PGE2
concentration in GCF was 2.2 ng/ml in AgP patients and 0.7 ng/
ml in healthy controls as determined by LC-MS.
In the present study, the concentrations of the mono-hydrox-
ylated PUFA-metabolites; 5- and 12- HETE were mainly found in
higher levels in GCF and serum, while 15-HETE was found in
significantly higher levels in all samples of the AgP patients. A
positive association with high levels of HETEs has also been
reported in other types of disease with an inflammatory
component [38,39]. Here we report that LTB4 was markedly
increased in saliva samples of AgP patients, and its potential as an
important marker for diagnosing periodontal disease activity
should be further investigated. High concentrations of PGs, LTB4
and cysteinyl-leukotrienes have been reported to promote the
accumulation of inflammatory cells such as polymorphonuclear
leukocytes (PMNs) by increasing the blood flow and vascular
permeability [40].
While initial fluid accumulation in the periodontal pocket seems
to represent a transudate of interstitial fluid produced by an
osmotic gradient leading to similar concentrations of for instance
proteins in GCF and interstitial fluid, GCF is regarded as a serum
exudate during inflammatory processes, with similar protein
concentrations as in serum. This may also apply to the similarities
in concentrations of lipid molecules in GCF and serum. Based on
these findings, and with the techniques used in this study, GCF
seems to be the most reliable biological fluid to reflect the local
destruction (reviewed by Griffiths [41]).
The PMNs underlying the junctional epithelium in the
periodontium represent the first line of defense against periodontal
pathogens [42]. Transmigration of PMNs across epithelial surfaces
represents a shared phenomenon among inflammatory mucosal
Table 2. Cont.
AgP HC P value
(n =16) ng/ml (n=12) ng/ml
Oxidative stress marker 8iPGF2 0.0360.04 0.0260.00{ 0.165
8iPGF3 3.93610.35 0.9161.58{ 0.242
The concentration of lipid mediators in saliva of aggressive periodontitis (AgP) patients and healthy controls (HC) was measured by HPLC-MS-MS. Results in ng/ml are
expressed as mean 6 SD. * Significantly different (P,0.05, Mann Whitney test). {Various values below the quantification limit set to 0.02 ng/ml. ** These derivatives
may partly origin from autooxidation.
doi:10.1371/journal.pone.0070838.t002
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Table 3. Concentration of lipid mediators in serum samples.
AgP HC P value
(n =16) ng/ml (n=12) ng/ml
PUFAs AA 855.46325.0 472.66261.2 0.002*
EPA 33.9633.4 8.266.9 0.001*
DHA 175.76112.7 82.2661.0 0.003*
LA 318.96210.1 225.46148.7 0.129
5-lipoxygenase pathway 5-HETE 24.1636.1 0.460.2 0.000*
LTB4 0.360.3 0.260.2{ 0.500
20-OH-LTB4 0.560.6 0.360.3{ 0.186
20-COOH-LTB4 1.662.2 2.562.0 0.111
LTC4 0.160.1 0.160.1{ 0.926
5-oxoETE** 0.560.4 0.260.2{ 0.028*
LXB4 0.260.2 0.560.1{ 0.550
LXA4 1.161.3 0.160.2{ 0.030*
5-HEPE 1.061.4 0.160.1{ 0.007*
LTB5 0.160.0 0.160.1{ 0.391
LXA5 0.160.1 0.260.4 0.938
4-HDHA 6.369.2 0.160.0{ 0.002*
8-hydroxylation pathway 8-HETE 1.661.2 0.460.3 0.001*
8-HEPE 0.760.6 0.360.4{ 0.047*
10-HDHA 0.460.3 0.160.1{ 0.019*
PD1 0.460.5 0.160.1{ 0.074
12-lipoxygenase pathway 12-HETE 259.86212.7 77.3676.2 0.005*
12-oxoETE** 2.862.2 2.363.0 0.100
HXA3 3.162.8 0.960.8 0.005*
HXB3 0.761.7 0.760.7 0.053
12-HEPE 3.263.2 1.462.0 0.011*
14-HDHA 5.065.3 1.761.6 0.017*
RvD1 0.160.2 0.260.3{ 0.856
RvD2 6.2622.8 0.961.9 0.383
MaR 0.260.1 0.160.1{ 0.134
9-HODE 4.664.1 2.664.1 0.008*
15-lipoxygenase pathway 15-HETE 5.564.4 1.361.3 0.001*
15-oxoETE** 0.961.3 0.160.1{ 0.037*
15-HEPE 0.360.4 0.260.1{ 0.174
17-HDHA 0.860.8 0.260.1{ 0.003*
13-HODE 4.564.0 1.6 61.0 0.005*
13-oxoODE** 11.269.0 5.063.6 0.038*
Cyclooxygenase pathway PGD2 2.462.1 1.961.2 0.626
PGE2 4.865.6 1.961.3 0.129
d15d12PGD2 2.562.1 0.960.6{ 0.002*
PGJ2 0.260.2 0.160.1{ 0.163
d15d12PGJ2 0.160.0 0.160.0{ 0.975
TXB2 200.56151.7 138.96191.9 0.058
PGF2 0.460.3 0.3660.3{ 0.207
PGE3 0.760.6 1.561.7 0.182
Alternative pathways 20-HETE 0.460.6 0.460.3{ 0.756
20-COOH-AA 5.464.7 1.861.8{ 0.001*
18-HEPE 0.560.3 0.360.4{ 0.003*
20-HDHA 0.660.6 0.160.1{ 0.001*
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conditions. In order to be recruited to the site of the battle, the
cells depend on chemotactic signals [43]. Hepoxilin A3 (HXA3)
has been shown to be a potent chemoattractant for PMNs. In our
study, the concentration of HXA3 in GCF was not significant
different between patients and controls. In serum, however, the
concentration of HXA3 was higher in patients compared to
controls (P=0.005).
A balanced ratio between n3- and n6-PUFAs is suggested by
World Health Organization (WHO) to decrease risk of coronary
heart disease (WHO 1995). Recently, resolution actions in
periodontal disease have been credited to products from the n3-
PUFAs [30]. The finding in the present study further demon-
strated a possible effect of n3- to n6-PUFAs ratios in AgP patients.
Future studies are needed to confirm the effect of pro-resolution
vs. pro-inflammatory imbalance in different types of periodontal
diseases.
Conclusions
In the present study, we report on generally elevated levels of
eicosanoids and docosanoids and various n6- and n3-PUFAs in the
GCF, saliva and serum of AgP patients compared with healthy
controls. In addition, there were significantly increased concen-
trations of PGE2 in GCF of AgP patients compared with healthy
controls determined via two independent methodological ap-
proaches. We demonstrated a lower ratio of precursors of pro-
resolution to pro-inflammatory lipid mediators in the GCF of AgP
patients compared with healthy controls. GCF seemed to be the
most reliable biological fluid for the assessment of the periodontal
condition. Findings from this study suggest that the ratio of the
precursor of pro-resolution vs. pro-inflammatory derivatives might
be appreciated as markers of local destruction in aggressive
periodontitis. Further studies focussing on various markers for
diseases severity in bigger cohorts of patients and correlating these
values with various lipid markers and ratios are in progress.
Materials and Methods
Study population
Nineteen AgP patients (4 males and 15 females) and 19 controls
(7 males and 12 females) were recruited consecutively from
patients seeking treatment at the University of Science and
Technology (UST), Omdurman, Khartoum, Sudan, from De-
cember 2008 to July 2009. To be included in the study, bleeding
on probing (BOP), probing pocket depth (PPD) and clinical
attachment level (CAL) $5 mm had to be present at least at one
central incisor and one first molar. The patients were all
,35 years (13–35 years; mean 23.466.4, median 23.5). The
Table 3. Cont.
AgP HC P value
(n =16) ng/ml (n=12) ng/ml
11-HETE 4.263.4 1.261.2 0.002*
Oxidative stress marker 8iPGF2 0.360.2 0.260.2{ 0.218
8iPGF3 0.860.9 1.361.4 0.371
The concentration of lipid mediators in serum of aggressive periodontitis (AgP) patients and healthy controls (HC) was measured by HPLC-MS-MS. Results in ng/ml are
expressed as mean 6 SD. * Significantly different (P,0.05, Mann Whitney test). {Various values below the quantification limit set to 0.05 ng/ml. ** These derivatives
may partly origin from autooxidation.
doi:10.1371/journal.pone.0070838.t003
Figure 2. ELISA analysis. Concentration (ng/ml) of PGE2 and LXA4 as determined by ELISA in gingival crevicular fluid (GCF) samples of aggressive
periodontitis (AgP) patients (black bar) and healthy controls (HC) (grey bar) * = P,0.05 by use of Mann-Whitney test.
doi:10.1371/journal.pone.0070838.g002
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number of teeth in each patient was from 21 and 28. The
diagnosis was confirmed by radiographs in addition to a full-
mouth clinical examination performed by the same dentist. Before
the examinations, intra-individual calibration of the examiner was
undertaken. Medical history was recorded for each patient, and
subjects who had received antibiotics or periodontal treatment
within the last three months before the examination, or were
pregnant or had any systemic disease that could affect the
progression of periodontal disease, were excluded. The 19 control
subjects were systemically healthy employees and students at UST,
with PPD #3 mm and CAL #2 mm for all teeth, and in most
cases all teeth were present.
Ethics Statement
Ethical approval was obtained from the Research Ethics
Committee at UST, Omdurman, Sudan, and the Regional
Committee for Medical Research Ethics (REK) Western Norway
(REK 177.04) (Bio bank no. 2355). Each subject signed an
informed consent written in their native language (Arabic) prior to
participation. On behalf of the young participants involved in the
study, the informed consents were assigned by their guardians, all
in accordance with the policy of REK, University of Bergen, and
UST.
Collection of biological materials
Saliva. Patients and controls were asked to rinse the mouth
with water before saliva was collected in a 10 ml sterile plastic
tube. The unstimulated whole saliva (UWS) samples were
processed the same day by centrifuging for 10 min at 30006g
(SUPERFIT centrifuge, Mumbai, India). Each supernatant was
dispersed into 4 tubes and stored in liquid nitrogen.
Blood. Peripheral blood was collected in vacutainer tubes; for
serum. The whole tubes were preserved at bench-side for not more
than two hours, and centrifuged for 10 min at 30006g (SUPER-
FIT centrifuge, Mumbai|, India). The tubes with serum were then
stored in liquid nitrogen.
Gingival crevicular fluid. A perio-paper (PERIOPAPERH
Gingival Fluid Collection Strips, Oraflow Inc, New York, USA)
was used for collection of GCF from the mesio-buccal site of
posterior teeth (mean pocket depth of sampled teeth was 5.9 mm).
Prior to the GCF collection, the area was isolated with cotton rolls
and exposed to a gentle air stream for five seconds. Then the
perio-paper was placed subgingivally for 10 seconds, before being
removed and stored in an empty tube in liquid nitrogen.
HPLC-ESI-MS-MS Analysis of free fatty acids, eicosanoids
and docosanoids in GCF, saliva and serum
The previously described procedure for the HPLC-ESI-MS-MS
method was followed with minor modifications [44], but including
complete quantification of the detected lipid derivatives.
Sample preparation. The whole analytical sample prepara-
tion procedure is based on an established method used for retinoid
quantification. Saliva samples were much lower in analyte
concentration and were dried in the Eppendorf concentrator
5301 (Eppendorf, Germany) at 45uC from 1.5 ml to 50 ml prior to
extraction. In summary, 50 ml of serum, saliva extract or GCF and
150 ml acetonitrile were shaken for 3 min, the precipitated protein
was centrifuged at 13.000 rpm, 4uC for 6 min, 130 mL of the
resulting supernatant was spiked with 10 ml isotope supernatant
mix, evaporated in Eppendorf reaction vials with an Eppendorf
concentrator at 30uC for ,60 min until the sample volume was
,10 ml. The Eppendorf concentrator was vented with argon to
prevent degradation of eicosanoids and docosanoids. The dried
extract was resuspended with approximately 25 ml of HPLC
solvent A [64.3% water (water, Chromasolv Plus from Sigma-
Aldrich, Hungary) and 35.5% acetonitrile (Merck KGaA,
Germany) and 0.2% formic acid (Fluka, Hungary)] to yield
35 ml, then vortexed (15 sec), shaken (3 min) and transferred into
micro injection inserts vials (Waters, Hungary). These glass vials
with the 35 ml extract were transferred into brown screw top vials
with PTFE/silicone septa sample (Waters, Hungary) and placed in
the pre-cooled (15uC) autosampler of the Waters 2695XE
separation module.
Figure 3. Ratio of n3- to n6-PUFAs in gingival crevicular fluid (GCF) (A), saliva (B) and serum (C) samples. The figure shows the ratios of
concentration of (EPA plus DHA) vs. AA in respective fluids of aggressive periodontitis patients (AgP, black bar) and healthy controls (HC, grey bar).
* = P,0.05 by use of Mann-Whitney test.
doi:10.1371/journal.pone.0070838.g003
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Table 4. Ratios and sums of lipid mediators from GCF – gingivial crevicular fluid, SAL – saliva, SER – serum of aggressive
periodontitis (AgP) patients and healthy controls (HC).
AgP HC P value
(n =16) (n=12)
AA-derived metabolite ratios 5-HETE/AA GCF 0.0160.01 0.0460.03 0.002*
SAL 0.0460.07 0.0260.03 0.199
SER 0.02±0.03 0.00160.001 0.010*
12-HETE/AA GCF 0.1460.16 0.2260.13 0.086
SAL 0.8361.75 1.4664.25 0.544
SER 0.29±0.20 0.1560.09 0.062
15-HETE/AA GCF 0.10±0.12 0.0460.04 0.178
SAL 0.04±0.09 0.0260.05 0.303
SER 0.01±0.00 0.00360.002 0.009*
EPA-derived metabolite ratios 18-HEPE/EPA GCF 19.67±31.59 13.90636.80 0.024*
SAL 0.4260.52 0.4560.31 0.802
SER 0.0360.03 0.0660.12 0.918
DHA-derived metabolite ratios 14-HDHA/DHA GCF 0.1360.11 0.2060.10 0.046*
SAL 0.3860.63 0.5861.58 0.613
SER 0.03±0.02 0.0260.02 0.654
17-HDHA/DHA GCF 0.37±0.54 0.1760.08 0.754
SAL 0.18±0.27 0.1060.22 0.345
SER 0.004±0.003 0.00360.003 0.227
PUFA-ratios EPA/AA GCF 0.0260.01 0.0360.02 0.016*
SAL 0.0260.02 0.0260.03 0.805
SER 0.03±0.03 0.0260.02 0.512
DHA/AA GCF 0.0960.06 0.1860.10 0.008*
SAL 0.1360.17 0.1360.04 0.982
SER 0.21±0.90 0.1960.09 0.629
Sum of PUFA-originating metabolites SUM HETEs GCF 3.13±2.56 1.0060.82 0.003*
SAL 3.76±2.85 2.6963.20 0.288
SER 260±236 1956208 0.002*
SUM HEPEs GCF 1.3861.91 1.4161.66 0.816
SAL 0.3060.29 0.6961.89 0.374
SER 5.70±5.12 4.0464.37 0.006*
SUM HDHAs GCF 0.71±0.45 0.3660.16 0.020*
SAL 0.23±0.18 0.2060.15 0.481
SER 13.0±14.8 2.2261.81 0.002*
HEPE or HDHA/HETE ratios HEPE/HETE ratio GCF 0.8361.16 1.5461.35 0.029*
SAL 0.1360.18 0.4560.90 0.128
SER 0.0360.01 0.0460.03 0.202
HDHA/HETE ratio GCF 0.2860.12 0.4560.17 0.005*
SAL 0.1060.13 0.1660.18 0.309
SER 0.05±0.04 0.0460.02 0.809
LOX/COX pathways 5-LOX pathway GCF 5.3±3.1 3.664.5 0.267
SAL 1.8±1.4 0.860.5 0.010*
SER 35.6±46.7 4.362.4 0.009*
12-LOX pathway GCF 11.2±9.1 6.963.3 0.129
SAL 6.2±5.2 5.364.9 0.582
SER 286±225 82.9681.4 0.001*
15-LOX pathway GCF 32.6±28.9 19.9611.2 0.166
SAL 12.5612.2 15.2620.3 0.619
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Chromatographic system. The HPLC system consisted of
a Waters 2695XE separation module (Waters, Hungary) including
a gradient pump, autosampler, degasser and a heated column
compartment. A MS-MS detector with an ESI ionizing option was
used (Micromass Quattro Ultima PT fromWaters, UK; a gift from
Biosystems Int., France) as a detector. The system was controlled
via the MassLynx software (Waters, Hungary).
HPLC conditions. The eluents were degassed in the Waters
2695XE separation module prior to mixing, then passed through
an in-line filter (1–2 mm; Knauer, Germany) before reaching the
analytical column (LiChroCART, 125 X 2 mm; Superspher 100,
RP-18, endcapped) from Merck KgaA (Germany) embedded in
the column compartment. A multilinear gradient was formed from
solvent A (see above) and solvent B (methanol; Merck KGaA
Germany). The gradient consisted of the following steps: 0.0 min
20% B, 3.0 min 20%B, 5.0 min 60%B, 15.0 min 100%B,
15.9 min 100%B and 16.0 min 5%B. The flow rate was adjusted
to 0.4 ml/min and the column was heated to 40uC. From the
same biological extract, 10 ml for each HPLC analysis was used.
This step was performed twice using the same HPLC conditions
and two different MS-MS analysis options for better resolution
and quantification of the various analytes.
MS options. The Micromass Quattro Ultima PT was
controlled via the MassLynx software. Argon with an inlet
pressure of 0.8 bar was used. ESI (electro spray ionization source,
Waters, Hungary) was vented by nitrogen continuously produced
by the nitrogen generator (Peak Scientific NM30 Nitrogen
generator) including compressor (Waters, Hungary) with the inlet
flow set at 3.6 e-3 mbar.
Multiple reaction monitoring settings: ESI, with a negative ESI
– setting, was performed with the HPLC eluent following the ion
source temperature of 85uC. The desolvation gas flow was 780 l/h,
the desolvation temperature was 400uC, the cone gas flow was 10
l/h, the capillary current was 3 mA, and the cone voltage was
50 V. Aperture voltage was set at 0 V and the RF lens voltage was
set at 35 V (for 1) and 0.2 V (for 2). The analyzer settings were
LM1 resolution 14.5; HM1 resolution 14.5; Ion energy 1 0.7;
entrance –1; collision 0 (collision parameters are set for each
substance at the MS – method parameters); exit 2; LM2 resolution
14.5; HM2 resolution 14.5; Ion energy 25.0 and a multiplier
energy of 650 V.
Multiple reaction monitoring settings for PUFA, eicosanoids/
docosanoids semi-quantification: Method A from 0.0 – 9.0 min for
PGF2 349.0 -.192.7, collision energy 22 eV; PD1 and PD1
isomers like PDX 359,0 -.153.3, collision energy 17 eV; TXB2
369.0 -.195.0, collision energy 13 eV, PGE3 349,0 -.233,0,
collision energy 17 eV, LXA4/LXB4 351,0 -.115.0, collision
energy 12 eV, 8iPGF3 351.0 -.193.0, collision energy 22 eV, 20-
COOH-LTB4 365.0 -.195.0, collision energy 13 eV, RvD1,
RvD2 375.0 -.141.3, collision energy 13 eV; RvE1 375.1 -
.141.3, collision energy 13 eV; from 9.0–12.5 min for 13-HODE
294.7 -.170.7, collision energy 16 eV; 9-HODE 294.7 -.194.7,
collision energy 16 eV; 5-HEPE 317.0 -.115.0, collision energy
17 eV; 12-HEPE 317.0 -.179.0, collision energy 17 eV; 15-
HEPE 317.0 -.219.0, collision energy 17 eV, LTC4 623.9 -
.272.0, collision energy 14 eV from 12.5–16.0 min for LA 279.3
-.279.0, collision energy 10 eV; 8-HEPE 317.0 -.255.0, collision
energy 17 eV, 18-HEPE 317.0 -.259.0, collision energy 17 eV; 5-
oxoETE, 12-oxoETE and 15-oxoETE 317.0 -.273.0, collision
energy 17 eV, 20-HETE 319.0 .245.0, collision energy 10 eV;
LTC4 623.9 -.272.0, collision energy 14 eV; LTE4 438.0 -
.333.0, collision energy 13 eV from 12.5–16.0 min for LA 279.3 -
.59.2, collision energy 25 eV; EPA 301.0 -.203.2, collision
energy 12 eV; AA 303.0 -.259.3, collision energy 11 eV, DHA
327.1 -.29.3, collision energy 14 eV.
Method B from 0.0–9.8 min for PGE2, d15d12PGD2, PGD2,
d15d12PGJ2, PGJ2 315.0 -.271.3, collision energy 13 eV; LTB5
333.0 -.195.0, collision energy 13 eV; LTB4 335.0 -.195.0,
collision energy 13 eV; RvE1 349.1 -.195.3, collision energy
13 eV; HXA3, HXB3, 20-COOH-AA 335.0 -.273.3, collision
energy 13 eV; LXA5 349.0 -.115.0, collision energy 12 eV; 20-
OH-LTB4 351.0 -.195.0, collision energy 13 eV; MaR 359.0 -
.250.0, collision energy 13 eV; from 9.8–12.5 min for 5-HETE
318.7 -.115.0, collision energy 14 eV; 8-HETE 319.0 -.155.0,
collision energy 14 eV; 11-HETE 319.0 -.167.0, collision energy
14 eV; 12-HETE 319.0 -.179.0, collision energy 14 eV; 15-
HETE 319.0 -.218.9, collision energy 11 eV; 4-HDHA 343.0 -
.101.0, collision energy 10 eV; 10-HDHA 343.0 -.181.0,
collision energy 10 eV; 14-HDHA 343.0 -.205.0, collision energy
10 eV; 17-HDHA 343.0 -.245.0, collision energy 14 eV, 20-
HDHA 343.0 -.285.0, collision energy 10 eV; 13-oxoODE 293.0
-.249.0, collision energy 17 eV and from 12.5–16.0 min for LA
279.3 -.59.2, collision energy 25 eV; EPA 301.0 -.203.2,
collision energy 12 eV, AA 303.0 -.259.3, collision energy 11
eV, DHA 327.1 -.229.3, collision energy 14 eV.
Standard solutions. Stock solutions of the PUFAs, eicosa-
noids and docosanoids were prepared by dissolving the solutions
obtained from Cayman-Chemicals (Estonia), BioMol International
(Kastel-Med KFT, Budapest, H), Sigma-Aldrich (Budapest H),
Larodan Lipids (Malmo¨, Sweden) and Dr. Charles Serhan
(Harvard, USA) with methanol to yield a final concentration of
10 mg/ml. All stock solutions were stored in darkness at 280uC.
The reference PUFAs, eicosanoids and docosanoids were used for
the assay validation.
Quantification. Individual eicosanoids and docosanoids
were quantified based on the determination of the ‘‘Area Under
Table 4. Cont.
AgP HC P value
(n =16) (n=12)
SER 23.2±16.3 7.964.8 0.001*
COX pathway GCF 5.8±2.7 4.161.9 0.037*
SAL 4.5±10.5 1.361.7 0.218
SER 212±153 1376190 0.207
Ratios of mono-hydroxylated PUFA metabolites or PUFAs vs. PUFAs; sums of mono-hydroxylated PUFA-metabolites of AA, EPA and DHA and their calculated ratios;
summarised metabolites originating from 5-, 12-, 15-LOX and COX metabolic pathways are shown. Data are presented in mean 6 sd. * significant different (P,0.05,
Mann Whitney test). Numbers in bold indicates increased values while italics indicates reduced values of AgP patients vs. healthy controls.
doi:10.1371/journal.pone.0070838.t004
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the Curve’’ (AUC) and compared with the AUC of standard
compounds. To ensure optimal extraction isotope labelled
standard compounds were used. This analytical procedure was
established for liquids and tissue analysis [45].
ELISA
Levels of PGE2 and LXA4 in GCF. Perio-papers saturated
with GCF from AgP patients and controls were immersed in
12 mM (pH 7.6) Tris buffer. The lipids recovered from the GCF
samples were diluted in the assay buffer of the ELISA kit; 10 times
for the analysis of PGE2 and 5 times for the LXA4. The PGE2 and
LXA4 were quantified by the competitive ELISA (Neogen
Corporation, Nandino Blvd., Lexington KY, USA) according to
instructions provided by the manufacturer. All GCF samples were
run in duplicate and measured by FLUOstar OPTIMA, and data
were reported in ng/ml.
Statistical analysis
Values which were determined under the detection limit were
replaced with values which present half of our quantification limit:
0.02 ng/ml for saliva and 0.05 ng/ml for GCF and serum. The
difference in significance between AgP and healthy controls was
determined by Predictive Analytics Software (PASW) version 18,
using the Mann Whitney test. P values ,0.05 were considered
statistically significant.
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